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Background: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely
compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on
health-related quality of life (HRQL). The objective of this study was to describe this impact using the Hunter
Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire and a range of standard
validated questionnaires previously used in paediatric populations.
Methods: Clinical and demographic characteristics collected in a clinical trial and responses to four HRQL
questionnaires completed both by patients and parents prior to enzyme replacement treatment were used. The
association between questionnaire scores and clinical function parameters were tested using Spearman rank-order
correlations. Results were compared to scores in other paediatric populations with chronic conditions obtained
through a targeted literature search of published studies.
Results: Overall, 96 male patients with MPS II and their parents were enrolled in the trial. All parents completed the
questionnaires and 53 patients above 12 years old also completed the self-reported versions. Parents’ and patients’
responses were analysed separately and results were very similar. Dysfunction according to the HS-FOCUS and the
CHAQ was most pronounced in the physical function domains. Very low scores were reported in the Self Esteem
and Family Cohesion domains in the CHQ and HUI3 disutility values indicated a moderate impact. Scores reported
by patients and their parents were consistently lower than scores in the other paediatric populations identified
(except the parent-reported Behaviour score); and considerably lower than normative values.
Conclusions: This study describes the impact on HRQL in patients with MPS II and provides a broader context by
comparing it with that of other chronic paediatric diseases. Physical function and the ability to perform day-to-day
activities were the most affected areas and a considerable impact on the psychological aspects of patients’ HRQL
was also found, with a higher level of impairment across most dimensions (particularly Pain and Self Esteem) than
that of other paediatric populations. Such humanistic data provide increasingly important support for establishing
priorities for health care spending, and as a component of health economic analysis.
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Hunter syndrome is a rare metabolic disease that can se-
verely compromise health, well-being and life expectancy.
Also called mucopolysaccharidosis type II (MPS II), it has
an X-linked recessive inheritance pattern, occurs primarily
in males [1] (with an estimated incidence of 1 per 162,000
births) and is classified as an orphan disease [2]. It is
caused by a deficiency of iduronate-2-sulfatase (I2S), a
lysosomal enzyme that cleaves O-linked sulfate moieties
from the glycosaminoglycans (GAGs) dermatan sulphate
and heparan sulphate, the first step in their degradative
pathway. This abnormality leads to accumulation of GAGs
within almost all tissues and organs, resulting in the
multisystem manifestations of MPS II.
The clinical picture includes distinctive facial features,
relatively large weight and length parameters at birth,
and a protuberance of the tongue that can impair both
swallowing and the ability to speak clearly [3,4]. Hearing
impairment is also common, with one study finding that
24% of patients had mild hearing loss, 31% moderate
and 22% severe (using the World Health Organization
International Classification of Impairment, Disability
and Handicap [WHO-ICIDH] classification) [5,6]; this
problem may go undetected, with potentially major ad-
verse consequences for speech, language and cognitive
development. The continuing build-up of GAGs in
organs leads to a decline in cardiac function, breathing
problems during sleep, abdominal distension, and joint
stiffness that affects walking and manual dexterity.
Early childhood may see the emergence of an inability
to keep up with peers in activities requiring physical
exertion. Later, the ability to walk even short distances
may be lost and many patients eventually become
wheelchair-dependent. The progressive decrease in joint
mobility may prevent affected individuals from independ-
ently performing self-care (e.g., dressing, toilet care
and personal grooming). Also, MPS II is associated with
chronic, severely diminished endurance that hinders
performance of day-to-day activities.
Although MPS II is characterised by such clinical
features, its presentation, severity and prognosis are
heterogeneous. For example, in the so-called ‘severe’
phenotype, onset (typically at 2 to 4 years of age) with
somatic features is followed by neurological problems
and cognitive impairment by the age of 6 years, and
death within the first two decades of life (usually from
obstructive airway disease or cardiac failure). By contrast,
while the ‘attenuated’ phenotype may be associated
with somatic features, patients with it generally have
little neurological involvement, are of normal intelligence
and usually survive into adulthood [7].
Traditionally, treatment for MPS II has targeted the
symptoms, with the aim of providing palliative benefit.
However, in recent years, clinical trials have demon-strated improvements in selected laboratory markers,
certain somatic features and measures of clinical function
with the use of enzyme replacement therapy (ERT)
comprising regular intravenous administration of idur-
sulfase, a recombinant form of human I2S. While these
results are important, it is unclear to what extent they
are mirrored by improvements in health-related quality
of life (HRQL) [7-10]. In addition, to date, little evidence
has been published on the nature and severity of the
effect of MPS II on humanistic measures such as HRQL
[11,12] – a significant knowledge gap given the disabling
and life-limiting effects of the disease.
The objective of this study was, therefore, to describe
the effect of MPS II on HRQL to increase understand-
ing of the disease and the need for treatment to be ini-
tiated in the clinical setting. From the patient and
family perspective, highlighting the impact of MPS II
on HRQL may help to identify specific areas with diffi-
culties they might encounter in order to better main-
tain functioning and to provide the most appropriate
support.Methods
Data collected between September 2003 and March
2004 at the time of enrolment into a clinical trial [13]
were used to describe the impact of MPS II on HRQL.
Participants were male patients with biochemical and
clinical evidence of MPS II and a forced vital capacity
(FVC) of < 80% of predicted and their parents/caregivers.
Data used in this study included patient characteristics,
clinical markers and HRQL measures at the time of trial
enrolment. Parents/caregivers of patients of all ages
responded to the parent-reported versions of the HRQL
measures, and only patients aged 12 years or older
responded to the self-reported versions. At the time of
this study, patients received treatment for joint pain and
other indications but none of them ERT.
Results were then compared with published data
using the same questionnaires in other paediatric pop-
ulations with chronic conditions such as diabetes (type
I), attention deficit hyperactivity disorder, asthma and
juvenile idiopathic arthritis as well as published nor-
mative values. Similar to the current study, the ques-
tionnaires had been completed by patients themselves
or by their caregivers (e.g., parents). This comparison
was conducted in order to provide a broader context
of the burden of illness of suffering from MPS II.HRQL Measures
The HRQL measures of this study included one
disease-specific and three generic questionnaires, and
both the self-reported and parent/caregiver versions:
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Understanding Scale (HS-FOCUS)
The Hunter Syndrome-Functional Outcomes for Clinical
Understanding Scale (HS-FOCUS) was developed to
capture the impact of MPS II on function [unpublished
observations]. The final patient and parent versions of
the instrument contain six domains measuring func-
tional status (Walking/Standing; Reach/Grip; Sleeping;
Schooling/Work; Activities; Breathing) and two add-
itional domains measuring Satisfaction and Botheredness
with the identified function domains. These were not
used in the analyses as assessed by clinical experts be-
cause they did not accurately reflect the level of satisfac-
tion or botheredness [14]. Each item is scored from 0 to
4, with 0 signifying an ability to complete the activity-
related functions ‘without ANY difficulty’ and 4 as being
‘UNABLE to do so’. Complete item responses are aver-
aged to calculate the six individual function domain
scores and the Overall Function score, with higher scores
representing a higher degree of incapacity. If more than
half of the items for a function domain are missing or
marked ‘not applicable’, that domain score is deemed to
be ‘missing’ and not included in the analysis.
The Childhood Health Assessment Questionnaire (CHAQ)
The Childhood Health Assessment Questionnaire (CHAQ)
was initially developed for assessing juvenile idiopathic
arthritis, from the perspective of the parent or patient,
and has been previously applied to other chronic disabling
conditions such as MPS II [15]. It is a 30-item instru-
ment that measures functional capacity and independence
in activities of daily life across eight domains: Dressing
and Grooming; Getting Up; Eating; Walking; Reach;
Grip; Hygiene and Activities. For each domain, there is
a 4-level difficulty scale that is scored from 0 to 3, with 0
corresponding to ‘without any difficulty’ and 3 to ‘unable
to do’. An additional question asks for any aids or devices
children usually use for any of the above activities,
which is used to adjust the scores of the domains into
the CHAQ disability index score (CHAQ DIS). This is
used as the outcome measure of functional disabilities
in severely disabled patients, with a scale from 0 to 3,
where 3 represents the worst functions. CHAQ also
presents two visual analogue scales for pain evaluation
and overall well-being evaluation, where 0 represents
‘no pain’ and ‘doing very well’ and 100 represents ‘very
severe pain’ and feeling ‘very poor’.
Childhood Health Questionnaire (CHQ)
The Child Health Questionnaire (CHQ) is a family of
generic quality-of-life instruments designed to assess
physical and psychosocial health status for children and
is normalised for those aged 5–18 years [16]. The reli-
ability and validity of the CHQ has been extensivelydocumented across a wide range of conditions, including
MPS II [17] and other rare disorders such as the evalu-
ation of ERT in Niemann-Pick disease. The version for
children (CHQ-CF87) includes 12 health concepts: 10
multi-item scales [Physical Functioning (PF); Role/
Social–Emotional (RE); Role/Social–Behavioural (RB);
Role/Social–Physical (RP); Bodily Pain (BP); General
Behaviour (BE); Mental Health (MH); Self Esteem (SE);
General Health Perceptions (GH); Family Activities
(FA)] and two single-item scales: Change in Health
(CH) and Family Cohesion (FC). The parent or caregiver
form (CHQ-PF50) includes 14 health concepts and
HRQL impacts, comprising those in the children version
plus two additional multi-item scales: Parental Impact–
Emotional (PE) and Parental Impact–Time (PT). Indi-
vidual scale scores can be analysed separately, or combined
to derive an overall physical and psychosocial score,
termed PhS and PsS, respectively. Scores range from 0
to 100, with higher scores reflecting better health.
Health Utilities Index (HUI)
The Health Utilities Index (HUI) includes both self and
proxy-assessed forms and is part of a family of generic
health profiles and preference-based systems intended
for describing the following: 1) the experience of patients
undergoing therapy; 2) long-term outcomes associated
with disease or therapy; 3) the efficacy, effectiveness and
efficiency of health care interventions; and 4) the health
status of general populations. HUI currently consists of
two systems, HUI2 and HUI3. This study used HUI3,
the more detailed descriptive system of the two, with
full structural independence, and normative population
available [18]. The scoring systems provide utility (prefer-
ence) scores on a scale on which death = 0.00 and perfect
health = 1.00. The health status classification and HRQL
scoring systems are generic in terms of applying to all
people aged 5 years and older in both clinical and general
populations. HUI3 has eight attributes (Vision; Hearing;
Speech; Ambulation; Dexterity; Emotion; Cognition;
Pain), with either five or six levels per attribute. Data
can be summarised by attribute using the single-
attribute HUI3 utility scores plus by the overall HRQL
utility score.
Clinical measures
The following objective clinical measures collected in
the clinical trial were also used to assess the validity of
the above-mentioned HRQL measures in describing the
effect of MPS II on patients’ HRQL.
Forced Vital Capacity (FVC)
Pulmonary function in terms of FVC was determined
by spirometry at the time of first ERT infusion. The
highest FVC reading of two measurements, reflecting
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analyses. The percentage of predicted FVC was used
instead of the absolute values (measured in litres), since
the latter are affected by extrapulmonary factors such
as age, height and gender, and cannot be compared be-
tween patients. Results nearest to 100% of the predicted
value represent the most normal function, and in the
trial, patients’ impairment of FVC was classified as mild
(between 70% and < 80%), moderate to moderate severe
(between 50% and 70%), and severe to very severe (less
than 50%).
Six-minute Walk Test (6MWT)
Patients underwent two measurements of the six-minute
walk test (6MWT) at the time of first ERT infusion.
The furthest distance walked in the two tests (reported
in metres) was used in all analyses, to reflect the patient’s
best physical performance. According to the 6MWT
results, a severity score of 1 was assigned if the distance
was ≥ 500 m (mild to normal severity), 2 if it was ≥ 300 m
to < 500 m (moderate severity), and 3 if it was < 300 m
(severe).
Joint Range of Motion (JROM)
Range of motion tests were employed to quantify the
musculoskeletal impairment associated with MPS II.
The joint range of motion (JROM) refers to the distance
and direction a joint can move to its full potential. Each
specific joint has a normal range of motion measurable
in degrees by using a goniometer. At baseline, a total of
23 motions were measured for the shoulder, elbow,
wrist, index finger, hip and ankle summarised in a global
JROM score. The measurements were performed two
times at separate visits. For each side of the body the
arithmetic mean for the two measurements at each visit
was calculated and the mean of these means was used in
the analysis. For the current analyses, the global JROM
scoring system was used (since individual joints can be
variably affected among patients), with range of motion
being reported as a percentage, with 100% indicating no
limitation in the joint motion.
Statistical analysis
Responses to the patient self-reported and parent-reported
study measures were analysed separately. Demographic
and clinical characteristics of patients were first investi-
gated. Mean and standard deviation of each domain
and overall scores of both the patient self-reported and
parent-reported versions of all study measures were exam-
ined separately, with the percentage of missing values.
Spearman rank-order correlations were used to test the
association between domain scores of all study measures
and the patient clinical function values. Data for com-
parison from other similar paediatric populations wereobtained from published studies. A targeted literature
search was conducted to identify studies that had used
the same HRQL measures in healthy children and ado-
lescents or in those who had other chronic conditions.
Data were analysed using Stata version 10.0 statistical
software (Stata, College Station, TX, USA).Results
Overall, 96 male patients and their parents were included
in this study. Participants in the trial were recruited
from sites in the United States (35%), United Kingdom
(23%), Brazil (22%) and Germany (20%).
Average age of the 96 patients was 14 years old, most
of them (82%) reported white ethnicity and were short
for their age. The MPS II diagnosis was confirmed on
average 10 years ago. Mean disease severity score (de-
fined as the sum of FVC severity score plus the 6MWT
severity score) was 4.1 (range 2 to 6), indicating the
population included in this study had the attenuated
form of MPS II. A subset of 53 patients were aged
12 years and above at the time of enrolment and com-
pleted the self-reported version of the HRQL measures.
This subset of patients was diagnosed on average for
almost 14 years and, due to the progressive nature of the
disease, were a bit more severe performing worse on the
clinical measures collected. Demographic and clinical
characteristics of all 96 patients and the subset of 53
patients can be found in Table 1.
The average age of the 96 parents/caregivers who
completed the parent version of the HRQL question-
naires was 42 years old and above 85% were females.
The scores of the four HRQL study measures were
examined. For the subgroup of 53 patients above 12 years
old, dysfunction according to the HS-FOCUS self-
reported responses was found most pronounced in
the Walking/Standing and Grip/Reach scores, and the
Overall Function score was 0.89. Disability showed a
similar pattern in the CHAQ, with scores for activities
of daily living including Hygiene, Reach and Dressing
and Grooming being the most affected. The average
CHAQ Pain scale score was 28.22 and the average
overall CHAQ score was 1.49. Results from the generic
CHQ showed that distress and dysfunction were most
pronounced with regards to Global Health, Physical
Functioning and Role/Social-limitations–Physical, as
well as Bodily Pain. Of note, very low scores were
reported in the Self Esteem and Family Cohesion do-
mains (patient self-reported scores 29 and 31, respect-
ively), suggesting a pronounced, detrimental impact on
the patients as well as their families and caregivers.
Similarly, the disutility values derived in the HUI3 indi-
cated a moderate impact, with a mean overall utility
score of 0.51.
Table 2 Spearman’s correlation between the patient
self-reported HS-FOCUS and clinical measures





48 −0.5840* −0.1334 −0.2084
Grip/Reach Function Score 48 −0.4014* −0.1210 −0.3376*
Sleeping Function Score 48 −0.1609 −0.1679 −0.1345
Schooling Work Function
Score
44 −0.3665* 0.1008 −0.1634
Activities Function Score 48 −0.5754* −0.1487 −0.1843
Breathing Function Score 45 −0.2219 −0.1158 −0.1842
Overall function score 48 −0.5871* −0.1717 −0.2961*
Child Satisfaction Score 47 0.2511 0.1124 0.0332
Child Botheredness Score 47 −0.4207* −0.0461 −0.2003
* Statistically significant at the 95% level of confidence.
Table 1 Patient characteristics
Mean SD Median Min Max % Missing
All patients (N = 96)
Age (yrs) 14.2 6.7 13.6 5.0 30.9 0.0
Age at diagnosis
(yrs)
4.3 3.7 3.0 0.0 20.0 2.1
Duration of MPS II
(yrs)
9.8 6.8 8.5 0.3 26.0 2.1
Height (cm) 127.8 14.8 126.5 99.06 170.0 12.5
Weight (kg) 35.9 13.2 32.7 19.0 78.0 7.3
6MWT (m) 400.3 100.3 407.5 37.0 588.0 2.1
% predicted FVC 56.2 14.9 54.8 16.0 90.8 2.1
Global JROM
score (%)
67.3 9.1 67.8 43.4 87.2 1.0
Patients above 12 years old who completed self-report
questionnaires (N = 53)
Age (yrs) 19.2 4.8 18.7 12.1 30.9 0.0
Age at
diagnosis (yrs)
5.5 4.5 4.0 0.0 20.0 3.8
Duration of
MPS II (yrs)
13.6 6.9 12.6 0.5 26.0 3.8
Height (cm) 135.1 13.8 132.5 109.2 170.0 11.3
Weight (kg) 43.6 12.9 38.8 26.8 78.0 9.4
6MWT (m) 377.9 116.5 395.0 37.0 588.0 1.9
% predicted FVC 50.1 13.1 50.0 16.0 79.2 1.9
Global JROM
score (%)
62.4 7.4 62.8 43.4 82.3 1.9
Raluy-Callado et al. Orphanet Journal of Rare Diseases 2013, 8:101 Page 5 of 10
http://www.ojrd.com/content/8/1/101For this subgroup of patients above 12 years old, par-
ent and patient self-reported scores were compared
and parent’s ratings suggested a slightly higher level of
dysfunction and distress than those of patients (data
not shown). The correlation coefficient between patient
self-reported and parent overall scores was found to be
positive ranging from 0.69 in HUI3 to 0.81 in CHAQ.
The functional areas with higher level of dysfunction
reported by parents on their 96 children were consistent
with those reported by the patients themselves. The
HS-FOCUS Overall Function score reported by parents
was 0.74, overall CHAQ score was 0.67 and the utility
score was 0.29. Similarly, the CHQ responses completed
by the parents were very low, also indicating pronounced
distress associated with MPS II across most of the CHQ
domains.
In order to assess the validity of these questionnaires
in describing the effect of MPS II on patients’ HRQL,
scores were correlated with objective clinical measures.
For the subgroup of patients 12 and above who completed
the patient self-reported versions, the correlation coef-
ficients between the disease-specific HS-FOCUS domains
and selected clinical parameters collected in the clinical
trial were found to follow the expected direction and werestatistically significant at 95% level of confidence, where
the strongest correlations were seen with the 6MWT,
and the global JROM score (Table 2). The Overall
Function scores of the HS-FOCUS were lower (indicating
less degree of incapacity) for higher distance walked in
6 minutes as recorded in the 6MWT (r = −0.6) and better
joint mobility as indicated by a global JROM closer to
100% (r = −0.3). The correlation between the other HRQL
measures and study clinical measures followed the same
expected direction indicating that patients who performed
worse in the clinical parameters were consistent in
reporting less quality of life as measured by the study
questionnaires. The largest coefficients were found be-
tween the 6MWT results and the Activities score of
the CHAQ (r = −0.6), and the JROM and the Physical
Functioning of the CHQ (r = 0.5). HRQL measures
were also correlated with the duration of illness since
diagnosis, and pair-wise correlations using the patient
self-reported responses were found to be positive and
statistically significant at 95% level of confidence for the
HS-FOCUS overall score, CHAQ VAS scales for pain
and well-being and CHQ Global Health Score. The
Overall utility score from the HUI3 was also statistically
significant and negative since lower utility indicates a
worse health state (data not shown).
To better understand and interpret these results, a
targeted literature search was conducted in order to
identify published studies that had used the same ques-
tionnaires as this study to assess aspects of HRQL in
children and adolescents to be able to compare them.
A total of five such publications involving the CHAQ
(one article), the CHQ (four articles) and the HU13
(two articles) were identified, with some of these articles
covering more than one questionnaire of interest.
The CHAQ-DIS scores reported by patients with
MPS II as collected in the trial indicated a 7-fold more
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and scores were similar in severity to that experienced
by patients with juvenile idiopathic arthritis [19] (CHAQ
DIS scores 1.5 vs. 1.7 for MPS II) (Table 3).
Of the four previous published studies identified
reporting CHQ scores, one included the patient-reported
CHQ-CF87 scores [20], and the other three the parent-
reported version CHQ-PF50 [21-23]. Normative values
were also identified, based on the parent-reported version
of the CHQ.
In general, scores reported by patients with MPS II and
their parents/caregivers were consistently lower than
scores in the other paediatric populations identified
(except the Behaviour score as reported by the parents);
and they were also considerably lower than the normative
values. Consistent with results obtained from the func-
tional measures (as described above), the Physical Func-
tioning and Role/Social-limitations–Physical in MPS II
were low (41 and 46 as reported by parents), compared
with the normative values that have been described as
96.1 and 93.6, respectively [24]. By comparison, several
paediatric asthma studies have shown values in these
domains of 85.5–93.7 and 86.5–92 [16]. The Self Esteem
and Family Cohesion scores were lower in MPS II than in
the other paediatric populations identified. Similarly, in re-
lation to Mental Health, there was a score of 66.9 in MPS
II, 69.9 in juvenile arthritis, and 69.7 in ADHD, compared
to a normal reference value of 78.5 (Figures 1 and 2).
Comparison between the HUI3 utility scores that par-
ents provided for their children with MPS II, with the
scores for other populations, corroborated published evi-
dence that hearing and related speech problems are a
major impairment in MPS II patients [25]. Other prom-
inent areas of impairment included dexterity and ambu-
lation (Figure 3). MPS II scores were lower in all HUI3
attributes than scores for patients with cancer, and lower
in all but the Pain scores compared to those in patients
with juvenile arthritis.
Discussion
This study shows that MPS II has a considerable impact
on both the physical functioning and psychological
aspects of patients’ HRQL. This dysfunction was evident
in scores for different disease-specific and general instru-
ments self-reported by patients or their parents/caregiversTable 3 Patient-reported CHAQ scores compared with
scores in a juvenile idiopathic arthritis population
CHAQ Juvenile idiopathic arthritis MPS II Healthy children
CHAQ DIS 1.73 1.49 0.20
VAS Pain 55.60 28.20 0.00
VAS
Well-being
51.60 34.40 0.00and these scores helped in identifying the most affected
areas. Also, even though the population described
(participants in clinical trial) had the attenuated form of
MPS II as dictated by the trial’s inclusion criteria, their
level of impairment across most dimensions (particularly
Pain and Self Esteem) was greater than that of other com-
parable paediatric populations.
Key findings of the study included confirmation that
physical function and the ability to perform day-to-day
activities were the most affected areas as described by all
of the study measures, with specific dysfunction with
regards to dexterity and upper body function. Pain and
discomfort were also amongst the most prominently
affected areas of HRQL and were of comparable severity
to that seen in juvenile refractory arthritis, a disease
well-known for its painful and incapacitating effects. The
study also corroborated published evidence on hearing im-
pairment associated with MPS II, by showing that Hearing
represented the most severe disutility among the HUI3
domains. This disability merits special attention given
its potentially harmful effect on children, especially with
regards to speech development and school performance if
the deficit is not promptly recognised [23,25].
The results also showed a psychological impact on
patients, with Self Esteem and Family Cohesion being
the most affected domains, having scores even lower than
those for physical function. This indicates that the dis-
ease severely affects self-image, which is particularly
concerning given that a lack of self esteem is likely to have
a damaging influence from childhood through adolescence
and into the longer term [26]. The low scores for Family
Cohesion provide an indirect indication of an important
additional dimension that needs consideration when
assessing the overall effect of MPS II on HRQL – the
impact on parents who act as caregivers. This adverse
influence was also reflected directly in responses to the
parent-specific questions in the CHQ, with lower reported
scores compared to those for other paediatric populations,
especially with respect to the amount of time parents
had for their own needs as a consequence of their
child’s condition. The fact that parents or caregivers
described the distress and dysfunction associated with
MPS II as slightly higher compared with corresponding
ratings made by patients themselves is a pattern that has
been observed in several published studies of families
where children have chronic diseases [27-30]. One explan-
ation for these findings may be that whilst patients may
learn to live and cope with their disease, parents have a
longer term perspective and are concerned about future
disability which may be incorporated in their assessment
thus generating worse scores compared with patient
ratings [30,31].
We believe that the present study has several key
















Figure 1 Patient-reported CHQ-CF87 scores compared with scores in a diabetic population.
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tunity to describe the burden of MPS II as experienced
by both patients themselves (at baseline of their partici-
pation in a clinical trial of ERT) and their caregivers,
and to compare this with physiological measures (from
the trial protocol). This approach has facilitated the


















Figure 2 Caregiver-reported CHQ-PF50 scores compared with proxy-r
proxy-reported normative values.isolation and, crucially, in comparison with other chronic
diseases. The combined use of disease-specific and generic
instruments is also a strength, and all of them strongly
correlated with objective clinical indicators supporting the
consistency of the results.
The HS-FOCUS questionnaire, for example, has pro-
vided detailed information on specific MPS II-associatedAsthma
ity Disorder MPSII











Juvenile Idiopathic Arthritis Oncology MPS II
Perfect health
Death
Figure 3 Caregiver-reported HUI3 utility values compared with caregiver-reported scores in other paediatric populations.
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CHQ are generic instruments that have been employed
in numerous paediatric populations and lend themselves
to comparisons of the HRQL burden across a range of
chronic conditions: they have, therefore, allowed the
impact on patients with MPS II to be gauged against
that in peers with other disabling diseases. In addition,
it is important to note the high correlation in this study
between study Overall Function scores in the HS-FOCUS
and objective measurements of functional capacity such as
the 6MWT, as well as a moderately high correlation with
the global JROM score as evidence of the validity of using
these instruments for measuring the adverse influence of
MPS II on patients’ lives and daily physical activities.
The correlation with JROM scores represents an im-
portant finding since this clearly suggest that joint stiff-
ness and flexion contractures can result in severe loss
of Overall Function as well as Grip/Reach function in
MPS II patients. Even though the correlation with lung
function did not reach statistical significance, the current
results show a relationship which is stronger than gen-
erally observed in e.g., chronic obstructive pulmonary
disease [32,33].
Some limitations of our findings are that they are
based wholly on patients with the attenuated form of
MPS II, and cannot be assumed to hold for those with
the severe form of the disease. However, given the
nature and range of clinical problems in severe MPS II,
it is reasonable to speculate that it too is associated with
considerable adverse effects on the HRQL of patientsand caregivers. Intelligence quotient of patients and
whether patients were living in a rural or urban environ-
ment might have influenced their quality of life, however,
this information was not available. Finally, the authors
recognize the possible language and cultural differences
between patients in the four countries where patients were
recruited; however, individual country samples were too
small to allow for subgroup analyses in this study.
Our study has key implications for clinical practice.
Previously, there has been surprisingly little published
on the impact of MPS II on patients’ HRQL, and nothing
on how the disease affects parents and/or caregivers.
Appropriate knowledge in these areas is obviously es-
sential in the management of any chronic disease. This
is particularly so for childhood conditions, where there
are consequences not just for the individual patient but
also for the HRQL of parents and other caregivers, and
for family life. With regards to MPS II, this study has
enabled the development of a clear and comprehensive
picture of the true impact of the disease and its conse-
quences. This deeper understanding should help paedi-
atricians, other clinicians and other professionals in
recognising the difficulties and needs of people with
MPS II and their caregivers, and in targeting support
and interventions for these people appropriately.
Our findings are also relevant to the advent of ERT as
a candidate for standard treatment of patients with MPS
II. This use has been advocated strongly by some opin-
ion leaders [34]. In reality, however, published trials of
the drug to date have provided only very limited
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portant aspects of HRQL [7-10]. Hence, it is reassuring
that our study found a clear association between key
clinical function measures for MPS II at baseline in one
of these trials and contemporaneous scores on HRQL
instruments. It follows that use of such instruments to
assess changes in HRQL should be a key part of further
evaluation of ERT. Justification of its routine use in a
disease as rare as MPS II will require a clear understand-
ing of how the HRQL of patients with MPS II and their
caregivers may benefit from the treatment, through thor-
ough and accurate evaluation over time. These results
have implications for other MPSs where similar results
may be found and conducting similar studies would be
important too. Other justifications include health eco-
nomic evidence on ERT, including assessments that
balance the cost of illness (which may be substantial)
against those of the value of the treatment. Ultimately, if
ERT is confirmed as standard therapy for MPS II, it will
be crucial to facilitate access to the treatment by ensur-
ing that health care providers are made more aware of
how this orphan disease affects patients and caregivers
in both the short and long term. In this broad context,
and for all these reasons, it is hard to overestimate the
importance of collecting patient data to describe accur-
ately the distress and dysfunction associated with MPS
II – the focus of our study.
Conclusion
In summary, this study demonstrates that it is possible to
quantify the HRQL impact of a rare disease by employing
standard validated questionnaires as a metric for quality of
life, including preference-based measures to capture the
disutility of a condition. The HRQL impact has been
described in detail for a group of patients with MPS II at
entry to a clinical trial and compared to physiological
measures gathered in that study, and with relevant other
chronic paediatric diseases. Findings showed that MPS
II has a considerable impact on both the physical func-
tioning and psychological aspects of patients’ HRQL, with
a higher level of impairment across most dimensions
(particularly Pain and Self Esteem) than that of other
comparable paediatric populations. Such humanistic data
are an increasingly important influence in the establish-
ment of priorities for health care spending, and as a
component of health economic analysis.
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